Biotech

Pomerantz LLP is investigating claims on behalf of investors of BELLUS Health Inc.  .  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980. The investigation concerns whether BELLUS Lidar and certain of its officers andor directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class ...

- Pomerantz LLP is investigating claims on behalf of investors of BELLUS Health Inc. ("BELLUS" or the "Company") (NASDAQ:  BLU).  Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 7980.

The investigation concerns whether BELLUS Lidar and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On July 6, 2020 , Bellus provided investors with an update regarding its product BLU-5937 , in development as a treatment for chronic cough.  Bellus announced that the drug had failed a Phase 2 study of chronic cough patients for whom other treatments had not worked.  Specifically, BLU-5937 was not significantly better than a placebo at reducing the frequency at which patients coughed.

On this news, Bellus's stock price fell $8.62 per share, or nearly 72%, to close at $3.40 per share on July 6, 2020 .

The Pomerantz Firm, with offices in New York , Chicago , Los Angeles , and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz , known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com

CONTACT:
Robert S. Willoughby
Pomerantz LLP
rswilloughby@pomlaw.com

Cision View original content: http://www.prnewswire.com/news-releases/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bellus-health-inc---blu-301249787.html

SOURCE Pomerantz LLP

News Provided by PR Newswire via QuoteMedia

BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

BriaCell Therapeutics Corp. Announces Results of 2022 Annual and Special Meeting of Shareholders

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") is pleased to announce that all resolutions proposed to shareholders at the Annual and Special Meeting of Shareholders (the "Meeting" ) held virtually via teleconference on January 18, 2022 were passed. Voting for each of the director nominees was as follows:

Nominee
For Withheld
Actual Percentage Actual Percentage
Dr. William V. Williams 2,286,353 97.68% 54,346 2.32%
Mr. Jamieson Bondarenko 2,286,214 97.67% 54,485 2.33%
Mr. Marc Lustig 2,285,435 97.64% 55,263 2.36%
Dr. Rebecca Taub 2,327,126 99.42% 13,573 0.58%
Mr. Vaughn C. Embro-Pantalony 2,285,426 97.64% 55,273 2.36%
Mr. Martin Schmieg 2,326,345 99.39% 14,353 0.61%
Dr. Jane Gross 2,327,674 99.44% 13,024 0.56%

Shareholders also voted in favour of: (i) setting the number of directors for the ensuing year at seven; (ii) re-appointing MNP LLP as auditors of the Company; (iii) approving the Company's stock option plan; and (iv) approving an amendment to the authorized share structure and articles of the Company by creating a new class of subordinate voting shares, and to vary the special rights and restrictions attached to the Common Shares to reflect the creation of the new class of shares, as more particularly described in the Company's Management Information Circular dated December 20, 2021 and posted to SEDAR on January 4, 2022. Please see the report of voting results filed under BriaCell's profile at www.sedar.com for the detailed results of these other matters voted on by shareholders at the Meeting.

Keep reading... Show less
Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board

Cardiol Therapeutics Appoints Thought Leaders in Cardiovascular Medicine to its Scientific Advisory Board

Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory therapies for the treatment of cardiovascular disease, today announced the appointment of Paul M. Ridker, MD, MPH, Bruce McManus, PhD, MD, and Joseph A. Hill, MD, PhD, to its Scientific Advisory Board (SAB).

"We are pleased to welcome distinguished thought leaders in cardiovascular medicine to our Scientific Advisory Board," said David Elsley, President and Chief Executive Officer of Cardiol Therapeutics. "Their expertise in cardiovascular research will provide invaluable guidance to our research and clinical programs focused on the development of novel anti-inflammatory therapies for the treatment of heart disease."

Keep reading... Show less

Gilead Sciences to Release Fourth Quarter & Full Year 2021 Financial Results on Tuesday, February 1, 2022

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2021 financial results will be released on Tuesday, February 1, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead's management will host a webcast to discuss the company's fourth quarter and full year 2021 financial results and will provide a business update.

A live webcast will be available on the investor relations page of http://investors.gilead.com and will be archived on www.gilead.com for one year.

Keep reading... Show less
Komo Plant Based Foods Launches U.S. Wholesale through RangeMe

Komo Plant Based Foods Launches U.S. Wholesale through RangeMe

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce that it is now available in the U.S. on RangeMe, the leading industry online platform that streamlines new product discovery between brands and retailers

Komo is a verified brand on RangeMe and currently has its full line of frozen meals uploaded on the platform, making its products visible to thousands of retail stores in the U.S. and Canada. Through this platform, U.S. buyers are able to discover new products and brands. U.S. retail chains on the RangeMe platform include Walmart, Whole Foods, Safeway, 7-Eleven, Kroger, Lowe's Foods, Harris Teeter, Albertsons, AHold USA, Food Lion, Publix, Meijer and Wakefern, as well as thousands of local and boutique retailers. Through RangeMe, Komo will be able to submit its products for retailer category reviews throughout the year.

Keep reading... Show less
Sirona Biochem Renews Agreement with CURE Intelligence for Marketing and Communications Support

Sirona Biochem Renews Agreement with CURE Intelligence for Marketing and Communications Support

Sirona Biochem Corp . (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF) (" Sirona ") is pleased to announce that it has renewed an agreement with Luxembourg-based analytics and marketing specialist CURE Intelligence for marketing intelligence services and communications support.

The agreement has been signed for an additional year of services.

Keep reading... Show less

U.S. FDA Approves RINVOQ® to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis

ABBVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved RINVOQ ® (upadacitinib) for the treatment of moderate to severe atopic dermatitis in adults and children 12 years of age and older whose disease did not respond to previous treatment and is not well controlled with other pills or injections, including biologic medicines, or when use of other pills or injections is not recommended. 1 RINVOQ 15 mg once daily can be initiated in adults and children 12 years of age and older weighing at least 40 kg. 1 In these children and adults less than 65 years of age who do not achieve an adequate response, the dose may be increased to 30 mg once daily. 1

"Early in my career as an allergist, I saw how relentless the itch and rash could be for my patients with moderate to severe atopic dermatitis yet had limited options to offer those whose disease could not be adequately controlled with systemic therapy," said Thomas Hudson , M.D., senior vice president, research and development, chief scientific officer, AbbVie. "This additional approval for RINVOQ provides a once-daily oral option that can significantly improve the debilitating itch and skin symptoms of atopic dermatitis. It's also a proud moment for AbbVie as we continue our efforts to improve care in this disease state and other chronic, immune-mediated conditions."

Keep reading... Show less

Latest Press Releases

Related News

×